Literature DB >> 15027030

Synthesis and receptor binding of IgG1 peptides derived from the IgG Fc region.

Katalin Uray1, Dávid Medgyesi, Agnes Hilbert, Gabriella Sármay, János Gergely, Ferenc Hudecz.   

Abstract

The IgG binding Fcgamma receptors (FcgammaRs) play a key role in defence against pathogens by linking humoral and cell-mediated immune responses. Impaired expression and/or function of FcgammaR may result in the development of pathological autoimmunity. Considering the functions of FcgammaRs, they are potential target molecules for drug design to aim at developing novel anti-inflammatory and immunomodulatory therapies. Previous data mostly obtained by X-ray analysis of ligand-receptor complexes indicate the profound role of the CH2 domain in binding to various FcgammaRs. Our aim was to localize linear segments, which are able to bind and also to modulate the function of the low affinity FcgammaRs, like FcgammaRIIb and FcgammaRIIIa. To this end a set of overlapping octapeptides was prepared corresponding to the 231-298 sequence of IgG1 CH2 domain and tested for binding to human recombinant soluble FcgammaRIIb. Based on these results, a second group of peptides was synthesized and their binding properties to recombinant soluble FcgammaRIIb, as well as to FcgammaRs expressed on the cell surface, was investigated. Here we report that peptide representing the Arg(255)-Ser(267) sequence of IgG1 is implicated in the binding to FcgammaRIIb. In addition we found that peptides corresponding to the Arg(255)-Ser(267), Lys(288)-Ser(298) or Pro(230)-Val(240) when presented in a multimeric form conjugated to branched chain polypeptide in uniformly oriented copies induced the release of TNFalpha, a pro-inflammatory cytokine from MonoMac monocyte cell line. These findings indicate that these conjugated peptides are able to cluster the activating FcgammaRs, and mediate FcgammaR dependent function. Peptide Arg(255)-Ser(267) can also be considered as a lead for further functional studies. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15027030     DOI: 10.1002/jmr.652

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  3 in total

1.  Increased survival and reduced renal injury in MRL/lpr mice treated with a human Fcγ receptor II (CD32) peptide.

Authors:  Jun Xi; Gai P Zhang; Song L Qiao; Jun Q Guo; Xuan N Wang; Yan Y Yang; Li N Zhang; Xian W Miao; Dong Zhao; Yu B Zhi; Shu J Cai; Jun Luo; Rui G Deng
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

2.  Binding site on human immunoglobulin G for the affinity ligand HWRGWV.

Authors:  Haiou Yang; Patrick V Gurgel; D Keith Williams; Benjamin G Bobay; John Cavanagh; David C Muddiman; Ruben G Carbonell
Journal:  J Mol Recognit       Date:  2010 May-Jun       Impact factor: 2.137

3.  Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist.

Authors:  Qinghua Wang; Kui Chen; Rui Liu; Fang Zhao; Sandeep Gupta; Nina Zhang; Gerald J Prud'homme
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.